Bristol Myers Squibb stock: EUR 57.43, up 0.37% premarket
Published on 11/17/2026 at 08:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst estimate moves higher
- Zacks Research raised its third-quarter 2027 EPS estimate from USD 1.55 to USD 1.74 while keeping a Hold rating.
- Bristol Myers Squibb reported third-quarter revenue of USD 13.07 billion and EPS of USD 1.35 on October 29, 2026.
- The company develops medicines for cancer, blood disorders, immune-mediated conditions and cardiovascular disease.
Bristol Myers Squibb stock traded at EUR 57.43 on Lang & Schwarz at 08:31:07 CET on Tuesday, November 17, 0.37 percent above the Xetra close of Monday, November 16.
In a report published on November 16, MarketBeat said Zacks Research lifted its third-quarter 2027 earnings-per-share estimate to USD 1.74 from USD 1.55. Zacks retained a Hold rating and also set its fiscal 2027 EPS estimate at USD 6.41.
Portfolio remains broad
Bristol Myers Squibb discovers, develops, manufactures and markets medicines in oncology, hematology, immunology and cardiovascular care. Its portfolio includes Opdivo, Yervoy, Eliquis and Orencia, giving investors exposure to several major therapeutic areas while patent expirations remain an important earnings factor.
The company reported third-quarter revenue of USD 13.07 billion and earnings of USD 1.35 per share on October 29, 2026. Revenue increased 6.9 percent from the prior-year quarter, according to MarketBeat.
For broader market context, follow the S&P 500.
